acalabrutinib
FDA Approves Calquence With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma
The FDA has granted traditional approval to Calquence with bendamustine and rituximab for adults with previously ...
JANUARY 21, 2025
BTK Inhibitors, Other Blood Cancer Drugs Are Being Tapped for COVID-19
Studies are underway exploring immunomodulating agents approved for hematologic malignancies in the treatment of ...
JULY 23, 2020
FDA Approves Calquence for CLL and SLL
The FDA granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with ...
NOVEMBER 21, 2019
FDA Approves BTK Inhibitor Calquence for Mantle Cell Lymphoma
The FDA granted accelerated approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with ...
NOVEMBER 1, 2017
Load more